In millions, except per share items | Dec-31-14 | Dec-31-13 | Dec-31-12 | Dec-31-11 | Dec-31-10 | Dec-31-09 |
| 10-K | 10-K | 10-K | 10-K | 10-K/A | S-1/A |
Operating activities | | | | | | |
Net loss | -135.6 | -51.9 | -36.8 | -11.2 | -16.0 | |
|
Adjustments to reconcile net loss to net cash used in operating activities: | | | | | | |
Amortization of debt discount and issuance cost | 0.9 | 0.3 | 0.3 | | | |
Non-cash in-process research and development | 53.0 | | | | | |
Stock-based compensation | 12.4 | 6.5 | 1.9 | 0.9 | 1.0 | |
Changes in assets and liabilities: | | | | | | |
Prepaid expenses and other current assets | -0.1 | -0.2 | 0.6 | -0.8 | -0.2 | |
Restricted cash | 5.1 | 10.9 | -8.6 | 14.4 | -21.8 | |
Other assets | -0.4 | | 0.0 | 0.0 | | |
Accounts payable and other accrued liabilities | 4.6 | 0.7 | 3.2 | 0.1 | 2.9 | |
Deferred development funds | -2.1 | -12.0 | 9.2 | -14.7 | 19.6 | |
Other liabilities | 1.3 | 0.0 | 0.0 | | | |
Net cash used in operating activities | -59.5 | -44.9 | -32.7 | -22.7 | 1.9 | |
|
Investing activities | | | | | | |
Purchases of marketable securities | -63.5 | -63.8 | | | | -34,645.0 |
Proceeds from sales of marketable securities | 47.3 | 7.4 | | | 12.7 | 31,058.0 |
Proceeds from maturities of marketable securities | 47.3 | 7.4 | | | 12.7 | 31,058.0 |
Investment in property and equipment | -2.1 | 0.0 | -0.2 | -0.7 | -0.1 | |
Net cash (used in) provided by investing activities | -18.3 | -56.5 | -0.2 | -0.7 | 12.6 | |
|
Financing activities | | | | | | |
Repayment of notes payable | -5.9 | -2.8 | | | | |
Net cash (used in) provided by financing activities | -4.5 | 133.6 | 77.6 | 36.3 | 0.1 | |
|
Repayment on credit facility | | | | | | |
Net (decrease) increase in cash and cash equivalents | -82.3 | 32.2 | 44.7 | 12.9 | 14.6 | |
Cash and cash equivalents at beginning of period | 111.5 | 79.3 | 34.6 | 21,676.0 | | |
Cash and cash equivalents at end of period | 29.2 | 111.5 | 79.3 | 34.6 | 21,676.0 | |
|
Supplemental disclosures | | | | | | |
Note payable issued to Bayer at fair value | 21.6 | | | | | |
Interest expense paid in cash | 0.8 | 1.3 | 0.1 | | | |